Benzodiazepine Use During Exposure Therapy for Specific Phobia
A patient beginning structured exposure therapy for a fear of flying wants medication to get through it. The pharmacology of fear extinction suggests that help might quietly undermine the very learning the therapy depends on.
Grace L., a 29-year-old woman, has a longstanding, isolated fear of flying that has kept her from attending her sister's wedding abroad and from a work promotion requiring regular travel. She has no other anxiety diagnosis, no panic attacks outside of flight-related contexts, and has just enrolled in a structured exposure-therapy program — her therapist has scheduled graduated exposure sessions culminating in an actual short flight in six weeks.
She is asking for a benzodiazepine to take before that flight, and before the exposure sessions leading up to it, reasoning that anything that gets her through the fear counts as progress. The pharmacology here cuts against her intuition: fear extinction, the actual mechanism exposure therapy relies on, requires the amygdala to learn a new association through genuine, unmedicated exposure to the feared stimulus and its anxiety — a benzodiazepine taken beforehand blunts exactly the anxious arousal that extinction learning needs, which real trial evidence suggests can undermine the durability of what exposure therapy is trying to build, even though it feels like it's helping in the moment.
She already missed her sister's wedding once for exactly this reason two years ago, a decision she still describes with real regret, which is part of why she's approaching this particular flight with more urgency than a first-time phobia presentation might typically carry — she doesn't want to arrive at the actual flight day having only half-prepared.
Her therapist, present for this consultation, adds that Grace has been a diligent, engaged participant in the sessions so far, completing every homework exercise between visits without prompting — context worth naming since it suggests her request for medication reflects genuine fear rather than any resistance to doing the actual work of exposure therapy.
Medicating around exposure therapy
Benzodiazepines taken before exposure sessions are a well-documented way to blunt the fear extinction learning the whole program depends on — state-dependent learning research consistently shows the association she needs to build, "flying is survivable and my anxiety comes down on its own," doesn't transfer well to an unmedicated state if she only ever experiences the exposure while sedated.
I understand the mechanism, but she is telling us directly that without something, she may not get on the plane at all in six weeks, which would mean losing the actual therapeutic exposure entirely rather than getting a slightly less durable version of it. A completed exposure with some medication on board still teaches something; an exposure that never happens teaches nothing.
The evidence supports a specific compromise here rather than an all-or-nothing choice: avoid benzodiazepines during the graduated in-session exposures, where extinction learning is the explicit goal and she has her therapist's support in the room, but keep a low-dose benzodiazepine available strictly as a last-resort option for the actual flight itself if her distress becomes genuinely intolerable — protecting the therapy's core mechanism where it matters most while not gambling the whole plan on her tolerance holding perfectly.
Agreed: no benzodiazepine during any of the graduated exposure sessions; a low-dose lorazepam prescription held in reserve for the culminating flight only, to be used solely if her distress becomes genuinely unmanageable rather than as a routine aid.